Article metrics

Download PDFPDF
639 Management of immune-related adverse events in patients with primary advanced or recurrent endometrial cancer: dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial

 

Online download statistics by month:

Online download statistics by month: March 2024 to June 2024

AbstractFullPdf
Mar 202415809
Apr 202413404
May 20248207
Jun 20244700
Total421020